The main purpose of Diabetablog is to keep track of diabetes-related research developments. I do want to encourage debate on certain topics through comments on posts... but I do not want a spam-ridden free-for-all. For that reason, here is my comment policy:

• When comments are enabled on a post, I welcome respectful, on-topic debate.
• All comments will be moderated. Note, that means your comment might not be immediately available (I do have to do stuff like sleep, hope you don't mind).
• Comments that are deemed to be spam will be deleted.
• All comments will be screened by some very clever AI for spam.
• Comments that include profanity, offensive language, pornographic content, misleading language or potentially libelous content will be deleted.
• Comments that attack an individual or entity will be deleted.
• Comments that troll or harass other contributors will be deleted. Please be respectful.
• Anonymous comments will be deleted. You will be required to include an email address before posting. Please also use your real name. I am only going to accept comments from people that make an effort to identify themselves.

I reserve the right to edit or delete comments without notice. I also reserve the right to change this policy as I see fit at any time. If you want to know about GDPR and other privacy issues go here.

If you have questions about this comments policy, let me know here.

Thanks,

Max Bingham (last updated June 2018)

I'm Max Bingham. I'm a science writer covering diabetes research. Much of the stuff I write about diabetes is published by the American Diabetes Association in their research journals. I've been writing about diabetes research since 2015 and it is fair to say there is ALOT of research that is published, it seems, almost daily. I've found that diabetes research is also a bit of a multi-armed beast as it covers everything from pharmaceutical developments, mechanistic studies, clinical trials, fundamental molecular studies, tech developments, nutrition, policy, software and even a bit of economics. 

There is no way I can cover all of it. There is too much and to be honest, some of it is so technical and/or incremental that the best place for those sorts of developments are the pages of scientific journals. However, there are the more noteworthy developments that are worth covering because they might have a significant impact for patients in the near term. That is the aim of the Diabetablog: to cover noteworthy developments relating to diabetes research.

While I am writing this blog as an ongoing effort to track developments in the shorter term, note that I also write columns for Clinical Diabetes and Diabetes Spectrum. There is a chance that some of the content found here will feed into those columns. So, respectively, I am on the look out for research that will inform primary care providers, and also a wider diabetes care team. Can a finding be used tomorrow to help patients with diabetes?

In general, the approach of Diabetablog will be to cover developments that are generally 'positive' for patient care. That does not mean I won't cover controversial or more general issues. I think it is good to be reminded of trends that underpin the area. I am less certain about covering mal-practice. There are better people out there that cover that stuff.

I'm expecting that the primary sources for this adventure will be peer-reviewed journals and other sources such as official reports. I will also use press statements/releases relating to such reports. I will also try to source direct quotes from authors and relevant others. It is unlikely that I will shrill about over-blown claims in press statements that are not backed up by (verifiable) scientific research (take note).

About Max Bingham

In a previous life, I qualified in 2003 with a PhD from The University of Reading, UK. The broad area of my research was gastrointestinal microbiology as well as food biosciences (hint: it stank). I moved to Rotterdam, The Netherlands in 2003 to complete a Marie-Curie Fellowship at Unilever R&D Vlaardingen in a slightly different research area (measurement sciences, yes, really). They evidently liked what I was doing as I stayed there as a research scientist working on microbiology, metabolomics and various nutrition-related topics up until 2010. That year, I decided to go freelance as a science writer and I've been doing it ever since. I have worked as a science writer/editor on numerous projects and topics.

Writing about Diabetes for the American Diabetes Association

I have been writing the 'In this Issue' section of both Diabetes and Diabetes Care since mid-2015. Grab a copy and you'll find the first article is 'In this Issue'. Here is an example from June 2018. I have also been writing for Clinical Diabetes and Diabetes Spectrum a section called Diabetes is Primary. Here is an example from the April 2018 issue of Clinical Diabetes.

Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text 

Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text 

Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text 

Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text Holding text